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Abstract
Background:  A series of 1H-imidazo- [4,5-c]quinolin-4-amine derivatives, represented by
LUF6000 (N-(3,4-dichloro-phenyl)-2-cyclohexyl-1H-imidazo [4,5-c]quinolin-4-amine), are allosteric
modulators of the human A3 adenosine receptor (AR). Here we studied the modulation by
LUF6000 of the maximum effect (Emax) of structurally diverse agonists at the A3 AR stably
expressed in CHO cells.
Results: In an assay of [35S]GTPγS binding, the Emax of the A3 AR agonist Cl-IB-MECA at the A3 AR
was lower than that of the non-selective AR agonist NECA. LUF6000 exerted an Emax-enhancing
effect at a concentration of 0.1 μM or higher, and was shown to increase the Emax of Cl-IB-MECA
and other low-efficacy agonists to a larger extent than that of the high-efficacy agonist NECA.
Interestingly, LUF6000 converted a nucleoside A3 AR antagonist MRS542, but not a non-nucleoside
antagonist MRS1220, into an agonist. LUF6000 alone did not show any effect. Mathematical
modeling was performed to explain the differential effects of LUF6000 on agonists with various
Emax. A simple explanation for the observation that LUF6000 has a much stronger effect on Cl-IB-
MECA than on NECA derived from the mathematical modeling is that NECA has relatively strong
intrinsic efficacy, such that the response is already close to the maximum response. Therefore,
LUF6000 cannot enhance Emax much further.
Conclusion: LUF6000 was found to be an allosteric enhancer of Emax of structurally diverse
agonists at the A3 AR, being more effective for low-Emax agonists than for high-Emax agonists.
LUF6000 was demonstrated to convert an antagonist into an agonist, which represents the first
example in G protein-coupled receptors. The observations from the present study are consistent
with that predicted by mathematical modeling.
Background
Adenosine receptors (ARs) are G protein-coupled recep-
tors, consisting of A1, A2A, A2B and A3 subtypes, activated
by the endogenous agonist adenosine and blocked by nat-
ural antagonists, such as caffeine and theophylline. A1 and
A3 subtypes are coupled to Gi/o proteins, while A2A and A2B
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subtypes are Gs protein-coupled. There is growing evi-
dence that they could be promising therapeutic targets in
a wide range of conditions [1-3].
Subtype-selective AR agonists have been developed, how-
ever, the selectivity for some organs or tissues is nearly
unachievable using orthosteric agonists that act directly at
the principal ligand binding site of the receptor. This is
due to the wide distribution of ARs and, indeed, a number
of agonists were discontinued after the initial phases of
clinical trials [3-5]. In contrast to directly-acting agonists,
allosteric modulators act at a distinct site on the receptor
protein to modulate the effect of a native agonist [6-10].
An advantage of an allosteric enhancer of a GPCR over its
native, orthosteric activator is that greater selectivity can
be achieved. This is due to allosteric sites being generally
less conserved than the orthosteric site in a particular
receptor family [8]. Furthermore, the allosteric enhancer
would enhance the action of the native agonist, but may
have no effect of its own on the unoccupied receptor.
Thus, the effect of an endogenous agonist, which may be
insufficient in a particular disease state, may be magnified
in a temporally and spatially specific manner through
allosteric modulation.
Allosteric modulation of membrane receptors is best char-
acterized in ligand-gated ion channels. The allosteric
enhancer diazepam, which enhances the CNS inhibitory
function of the endogenous γ-aminobutyric acid, is a pro-
totypic representative of the benzodiazepines, the most
widely prescribed sleep medications. In the GPCR field,
cinacalcet, an allosteric enhancer of the calcium-sensing
receptor (CaR), has recently been approved for the treat-
ment of secondary hyperparathyroidism in dialysis
patients suffering from chronic kidney disease [11]. In the
case of ARs, the A1 AR has been the most studied in this
context, and one of its allosteric enhancers, T62 (2-amino-
4,5,6,7-tetrahydrobenzo [b]thiophen-3-yl-(4-chlorophe-
nyl)methanone), has been in clinical trials for the treat-
ment of neuropathic pain. Numerous allosteric enhancers
and inhibitors for Class B and Class C GPCRs are also in
various phases of clinical trials for treatment of a number
of disorders [7,10,12-14].
Allosteric modulators for the A3 AR have been recently
identified and characterized [15]. One class of these allos-
teric modulators, including the 1H-imidazo- [4,5-c]quin-
olin-4-amine derivative DU124183, was found to
decrease agonist potency while enhancing its maximum
effect (Emax) [16]. Recently, a new series of the imidazo-
quinoline derivatives has been synthesized [17]. Several
of those allosteric modulators, represented by LUF6000,
were found to also enhance Emax but without affecting
agonist potency. Thus, the pharmacological profile as a
positive allosteric modulator of the A3 AR was superior to
that of DU124183. In this study, we extended our previ-
ous observations by studying the nature of the potentially
flexible modulation by LUF6000 of the agonists with a
selection of A3 AR agonists having a distribution of Emax
values in A3 AR-expressing CHO cells using a [35S]GTPγS
binding assay [18]. We learned that the degree of allosteric
enhancement is dependent on the orthosteric ligand
examined, which was quantified using a mathematical
model [19], adding further subtlety to this new concept of
GPCR regulation.
Results
AR agonists and allosteric modulators used in the present 
study
A number of nucleoside agonists and one non-nucleoside
agonist (LUF5833) used in the present study are shown in
Figure 1. The 5' -substituted adenosine derivative NECA is
a high-efficacy AR agonist. Medium or low efficacy ago-
nists include: an N6,2,5' -trisubstituted derivative Cl-IB-
MECA, a N6-monosubstituted adenosine derivative
MRS541, and a non-nucleoside agonist, LUF5833. In
addition to agonists, a nucleoside A3 AR antagonist (as
defined previously in adenylyl cyclase assays), MRS542,
[20] and a non-nucleoside antagonist MRS1220 were also
included. The allosteric modulator (Figure 1) used in the
present study is the imidazoquinoline derivative
LUF6000, which has been shown to retard agonist radio-
ligand dissociation and to increase agonist Emax, as dem-
onstrated using a cyclic AMP functional assay [17].
LUF6000 was relatively potent as an enhancer of A3 AR
agonist activity in comparison to its A3 AR antagonistic
properties. It did not bind appreciably at the other sub-
types of ARs.
Effects of LUF6000 on the Emax at the A3 AR of agonists 
with diverse structures studied with a [35S]GTPγS binding 
assay
The modulation by LUF6000 of the Emax of diverse ago-
nists at the A3 AR was studied using a [35S]GTPγS binding
assay, which directly reflects activation of Gi/o proteins.
We first compared the Emax-enhancing effects of LUF6000
under several experimental conditions: (a) addition of the
enhancer LUF6000 and an agonist Cl-IB-MECA simulta-
neously (Figure 2A); (b) pre-incubation of the enhancer
LUF6000 with membranes for 20 min before the addition
of the agonist to be incubated for another 30 min (Figure
2B); (c) pre-incubation of membranes with both
LUF6000 and an agonist for 30 min (Figure 2C). It was
found that LUF6000, at the concentration of 0.1 μM or
higher, produced a similar enhancement of the Emax of Cl-
IB-MECA under all of these conditions. Thus, the subse-
quent experiments were performed without the pre-incu-
bation of LUF6000 and/or agonist with membranes. Also,
a longer incubation time (90 min) did not cause further
stimulation, but increased the non-specific binding (dataBMC Pharmacology 2008, 8:20 http://www.biomedcentral.com/1471-2210/8/20
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not shown). The potency and Emax of Cl-IB-MECA to stim-
ulate [35S]GTPγS binding in the absence and presence of
various concentrations of LUF6000 are summarized in
Table 1.
LUF6000 had a less pronounced effect on the Emax of
NECA (Figure 2D), but showed a much larger effect on the
low-efficacy agonist MRS541 (Figure 2E) compared with
its effect on Cl-IB-MECA. MRS542, which has been shown
to be an antagonist previously as demonstrated in a cyclic
AMP assay [20], was also demonstrated to be an antago-
nist in the present GTPγS binding assay (Figure 3A and
Figure 3B). However, interestingly, MRS542 was con-
verted into an agonist by LUF6000 in a concentration-
dependent manner (Figure 2F). Additionally, LUF6000
also enhanced the stimulation of [35S]GTPγS binding
induced by the non-nucleoside agonist, LUF5833 (Figure
3E), whereas it had no effect on the non-nucleoside antag-
onists MRS1220 (Figure 3C) and MRS1191 (Figure 3D).
LUF6000, at concentrations from 0.1 to 10 μM, did not
show any effect on the basal level of A3 AR activation in
this [35S]GTPγS assay (Figure 3F). The potency and Emax of
various ligands in the absence and presence of various
concentrations of LUF6000 are summarized in Table 1.
The dose-response curves of NECA, Cl-IB-MECA,
MRS541, LUF6000 and MRS542 are shown in Figure 3F.
Cl-IB-MECA is only partially efficacious compared with
NECA in inducing [35S]GTPγS binding.
Chemical structures of the agonists, antagonists, and an allosteric modulator of the A3 adenosine receptor used in the present  study Figure 1
Chemical structures of the agonists, antagonists, and an allosteric modulator of the A3 adenosine receptor 
used in the present study.BMC Pharmacology 2008, 8:20 http://www.biomedcentral.com/1471-2210/8/20
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Effect of LUF6000 on agonist-induced activation of the human A3 AR studied with a [35S]GTPγS binding assay Figure 2
Effect of LUF6000 on agonist-induced activation of the human A3 AR studied with a [35S]GTPγS binding assay. 
Incubations were started by addition of the membrane suspension (5 μg protein/tube) to the test tubes, and carried out in 
duplicate for 30 min at 25°C, except for B and C in which LUF6000 or both LUF6000 and an agonist were incubated for 20 min 
with membranes and other components before the addition of [35S]GTPγS (final concentration 0.2 nM). The experimental pro-
cedures are described in the Materials and Methods section. Results were from 3–5 independent experiments performed in 
duplicate. The basal values typically ranged from 800 to 1200 cpm. The maximal values are typically from 2000 to 2500 cpm. A. 
Cl-IB-MECA. B. Cl-IB-MECA (LUF6000 was incubated with membranes 20 min before the addition of other components). C. 
Cl-IB-MECA (Both LUF6000 and Cl-IB-MECA were incubated 20 min with membranes before the addition of other ingredi-
ents); D. NECA; E. MRS541; MRS542. The maximum stimulation of NECA in the absence of enhancers was expressed as 100%.BMC Pharmacology 2008, 8:20 http://www.biomedcentral.com/1471-2210/8/20
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In order to confirm the effect of LUF6000 on the Emax of
the selective agonist Cl-IB-MECA at the A3 AR, we further
tested its effect on two other A3 AR selective agonists, IB-
MECA and inosine. It was demonstrated that IB-MECA
was almost as efficacious as Cl-IB-MECA, and LUF6000
showed similar effect on these two A3 AR agonists. Inosine
only showed a low Emax (< 10% of that of NECA). How-
ever, in the presence of 10 μM LUF6000, the Emax of inos-
ine was shown to be approximately 80% of the Emax of
NECA.
Unlike its effect on the A3 AR, LUF6000 did not affect the
Emax of two high-efficacy agonists CPA and CCPA or a low
efficacy agonist MRS541 to activate the A1 AR (Figure 4).
Mathematical modeling
The equations from Hall [19] were used to simulate vari-
ous experimental curves and to derive conditions in
which Emax and EC50 vary. Parameters in these equations
are as follows. L is the receptor isomerization constant
(the ratio of receptor in the active state over the inactive
state). K is the equilibrium association constant of ligand
A. M is the equilibrium association constant of ligand B
(allosteric modulator). α is the intrinsic efficacy of ligand
A. β is the intrinsic efficacy of ligand B. γ is the binding
cooperativity between A and B. δ is the activation cooper-
ativity between A and B. L is only related to the receptor.
The allosteric modulator brings three parameters, β, γ and
δ, to the system. The proportion of receptors in the active
state is:
This can be restated as:
Since LUF6000 did not affect the function of the A3 AR
when given alone, we concluded it has neutral intrinsic
efficacy (β = 1). Next we derived the conditions under
which the maximal effect (Emax) and observed potency of
an agonist can change in the presence of an allosteric
modulator. When there is a saturating concentration of
agonist in the absence of allosteric modulator, the propor-
tion of active receptor populations over all receptors is
given by:
When there is also an excess amount of allosteric modula-
tor, the proportion is given as:
Comparing these two equations, we learned that if
δ > 1, the maximum response increases;
δ = 1, the maximum response remains unchanged;
δ < 1, the maximum response decreases;
Based on Hall's model of allosteric modulation, the ago-
nist affinity ratio in the presence and absence of an allos-
teric modulator with neutral intrinsic efficacy is:
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Table 1: Effects of LUF6000 on the potency (-logEC50) and 
maximum effect (Emax) at the A3 AR of structurally diverse 
ligands measured with a [35S]GTPγS binding assay
Ligands Emax (%) -logEC50 (M)
Cl-IB-MECA 50.1 ± 2.4 7.52 ± 0.11
+LUF 0.1 μM 60.4 ± 3.7 7.62 ± 0.12
+LUF 0.3 μM 70.5 ± 5.2 7.54 ± 0.09
+LUF 1.0 μM 82.4 ± 7.3 7.55 ± 0.10
+LUF 3.0 μM 122 ± 3 7.20 ± 0.06
+LUF 10 μM 125 ± 2 7.21 ± 0.06
NECA 100 ± 3 6.79 ± 0.06
+LUF 1.0 μM 119 ± 7 6.81 ± 0.10
+LUF 10 μM 134 ± 5 6.61 ± 0.07
MRS541 24.3 ± 2.9 7.48 ± 0.31
+LUF 0.1 μM 30.0 ± 1.7 7.43 ± 0.25
+LUF 0.3 μM 45.0 ± 7.0 7.55 ± 0.22
+LUF 1.0 μM 72.5 ± 7.6 7.39 ± 0.16
+LUF 3.0 μM 116 ± 8 7.06 ± 0.11
+LUF 10 μM 121 ± 6 6.99 ± 0.11
MRS542 5.6 ± 2.5 NA
+LUF 0.1 μM 16.4 ± 3.1 NA
+LUF 0.3 μM 34.2 ± 5.4 6.41 ± 0.47
+LUF 1.0 μM 51.7 ± 4.1 7.12 ± 0.20
+LUF 3.0 μM 69.2 ± 4.5 7.14 ± 0.15
+LUF 10 μM 91.1 ± 4.1 6.82 ± 0.11
LUF5833 35.2 ± 5.2 6.02 ± 0.26
+LUF 0.1 μM 63.8 ± 5.2 5.91 ± 0.14
+LUF 1.0 μM 92.7 ± 9.7 5.92 ± 0.18
+LUF 10 μM 102 ± 7.6 5.99 ± 0.13
MRS1220 NA NA
+LUF 10 μMN A N A
The Emax of NECA in the absence of LUF6000 was expressed as 100%. 
Results are expressed as mean ± S.E. LUF, LUF6000; NA, not 
applicable.BMC Pharmacology 2008, 8:20 http://www.biomedcentral.com/1471-2210/8/20
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Effect of LUF6000 on various human A3 AR ligands, studied with a [35S]GTPγS binding assay Figure 3
Effect of LUF6000 on various human A3 AR ligands, studied with a [35S]GTPγS binding assay. Incubations were 
started by addition of the membrane suspension (5 μg protein/tube) to the test tubes, and carried out in duplicate for 30 min 
at 25°C. The experimental procedures are described in the Materials and Methods section. Results were from 3–5 independ-
ent experiments performed in duplicate. The basal values typically ranged from 800 to 1200 cpm. The maximal values are typi-
cally from 2000 to 2500 cpm.BMC Pharmacology 2008, 8:20 http://www.biomedcentral.com/1471-2210/8/20
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Effect of LUF6000 on agonist-induced activation of the human A1 AR studied with a [35S]GTPγS binding assay Figure 4
Effect of LUF6000 on agonist-induced activation of the human A1 AR studied with a [35S]GTPγS binding assay. 
Incubations were started by addition of the membrane suspension (5 μg protein/tube) to the test tubes, and carried out in 
duplicate for 30 min at 25°C. Results were from 3 independent experiments performed in duplicate. The basal values ranged 
from 700 to 1000 cpm. The maximal values are typically from 1500 to 1800 cpm.BMC Pharmacology 2008, 8:20 http://www.biomedcentral.com/1471-2210/8/20
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Thus, if
We also analyzed the condition in which an allosteric
modulator converts a neutral antagonist or even an
inverse agonist into an agonist. In the presence of excess
amount of an allosteric modulator, the window, i.e. dif-
ference in Emax, observed in the absence and presence of a
ligand in the orthosteric site is
When αδ > 1, agonism is observed. This implies that when
δ, the parameter for activation cooperativity, is large
enough, an allosteric modulator can convert a neutral
antagonist and an inverse agonist into agonists.
We simulated a number of experimental concentration-
effect curves as depicted in Figure 2, reflecting the use of
different agonists (Figure 5). We only varied the intrinsic
efficacy (α) of the orthosteric ligand A, i.e. for NECA, Cl-
IB-MECA, MRS541 and MRS542 α values were set to 500,
100, 50 and 5, respectivly. The values of the other param-
eters were as follows: L = 0.005; K = 1 × 108; M = 5 × 106;
β = 1; γ = 0.05; δ = 50; As is evident from Figure 5, these
settings allow for a simulation of concentration-effect
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Simulation of concentration-effect curves with MatLab Figure 5
Simulation of concentration-effect curves with MatLab. The equations from Hall (2000) were used to derive condi-
tions that vary in efficacy and potency. The parameters in these equations are explained and discussed in the text. Parts A, B, C 
and D mimic the experimental concentration-effect curves of Figures 2D, 2C, 2E and 2F, respectively.BMC Pharmacology 2008, 8:20 http://www.biomedcentral.com/1471-2210/8/20
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curves that closely resemble the ones obtained experimen-
tally.
Discussion
The result that LUF6000 alone did not show any agonist
activity indicates that, under physiological conditions
where the concentration of native adenosine is relatively
low, LUF6000 should have no effect. The fact that
LUF6000 showed significant enhancement of the Emax of
agonists, suggests that it could enhance agonist efficacy
under some pathophysiological conditions such as
ischemia and inflammation where concentrations of
endogenous agonists are highly elevated.
It is interesting that LUF6000 was shown to enhance the
Emax of low-efficacy agonists to a larger extent than that of
the high-efficacy agonists. Furthermore, LUF6000 was
demonstrated to be able to convert a nucleoside antago-
nist MRS542 into an agonist. The effect did not occur with
the non-nucleoside antagonists MRS1220 and MRS1191.
This may suggest that the nucleoside antagonist may have
a small residual activity that would normally be below the
detection threshold but could be greatly magnified in the
presence of LUF6000.
The ability of GPCRs to adopt various conformational
states, each with distinct pharmacological properties, and
the phenomenon of stabilization of a specific conforma-
tion of a GPCR by an allosteric enhancer have been well
documented [9,21].
Activation of a given GPCR could be accomplished with
an allosteric agonist, in addition an orthosteric agonist
[10,22-28]. Conversion of antagonists into agonists has
been demonstrated previously by site-directed mutagene-
sis of GPCRs [29-33] or by chemical modification of the
antagonists [20,34]. However, to our knowledge, there
has not been a report regarding this type of conversion by
an allosteric modulator, although an example of the con-
version of an agonist into antagonist by an allosteric mod-
ulator has been reported previously [35]. Thus, it is likely
that our finding that an allosteric enhancer can convert an
apparent antagonist into an agonist may be generalized to
other GPCRs. A better understanding of the conforma-
tional states and the mechanisms of GPCR activation will
facilitate the design of more effective and selective drugs.
A simple R⇔R* model representing the two conforma-
tional states (inactive R, and active R*) of the receptor has
been previously used to rationalize the effect of the A1 AR
enhancer PD81,723 [36]. PD81,723 alone behaves as an
allosteric agonist, promoting the A1 AR to its active confor-
mation (R*) and, thus, potentiates the A1 AR constitutive
receptor activity. However, LUF6000 alone does not acti-
vate the A3 AR. Thus, unlike PD81,723, which shifts the
receptor to the R* state directly, LUF6000 presumably
does not cause such a shift.
An extension of the two-state model of receptor activation
has been described by Hall [19] to account for the allos-
teric modulators affecting the agonist potency as well as
the intrinsic efficacy of agonists. Hall [19] suggested that
the most suitable assay system may be one with very low
receptor expression in which even highly efficacious ago-
nists are unable to fully activate the signal transduction
cascade. We have previously described that our cyclic AMP
functional assay system is an ideal model for the charac-
terization of the functional aspects of this class of allos-
teric modulators, especially the characterization of their
effects on maximal agonist efficacy due to the less-than-
complete inhibition of adenylyl cyclase by A3 AR agonists
[16,17]. The present study extended the previous one by
using the newly synthesized enhancer LUF6000 and struc-
turally diverse agonists and by testing the stimulation of
GTPγS binding. It was found that in the current
[35S]GTPγS binding assay system, none of the agonists
(previously assumed to be full or partial agonists mainly
based on a cyclic AMP functional assay) were fully effica-
cious, as the allosteric enhancer LUF6000 was able to
enhance the Emax of all agonists used. Thus, the current
[35S]GTPγS binding assay may represent the most suitable
assay system as Hall suggested [19], since even highly effi-
cacious agonists are unable to fully activate the signal
transduction cascade. The observations from the present
study are consistent with that predicted by Hall's model,
and thus, the equations from Hall [19] were used to sim-
ulate various experimental curves from the present study
and to derive conditions in which Emax and potency vary.
For the mathematical modeling, two independent param-
eters are necessary to simulate various effects on efficacy
and potency. The binding cooperativity shifts the potency
of the agonist. The activation coöperativity changes the
Emax that the agonist can achieve, as well as the potency of
the agonist. By contrast, the simple model of Ehlert for
allosteric modulation [37] uses only one parameter to
describe the property of allosteric modulation, so that it
cannot simulate the current experimental results. The sim-
ple model of allosteric modulation can only generate
curves with increased or decreased potency and efficacy at
the same time.
As demonstrated in the present study, NECA is more effi-
cacious than Cl-IB-MECA in stimulating G proteins as
measured in the [35S]GTPγS binding assay. An explana-
tion for the observation that LUF6000 has a much
stronger effect on Cl-IB-MECA than on NECA derives
from the mathematical modeling. NECA has a relatively
strong intrinsic efficacy, such that the response is alreadyBMC Pharmacology 2008, 8:20 http://www.biomedcentral.com/1471-2210/8/20
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close to the maximum response. Therefore, LUF6000 can-
not enhance Emax much further.
Conclusion
LUF6000 showed a flexible modulatory effect of efficacy
depending on the Emax of a given nucleoside derivative,
being more effective for low-Emax agonists than for high-
Emax agonists. The fact that LUF6000 did not show any
effect on the basal receptor activity, yet showed an
enhancement of agonist activity, suggests that such
enhancers could be safer drugs than orthosteric agonists.
The observations from the present study are consistent
with the quantitative prediction using Hall's model. A
simple explanation for the observation that LUF6000 has
a much stronger effect on Cl-IB-MECA than on NECA
derived from the mathematical modeling is that NECA
has relatively strong intrinsic efficacy, such that the
response is already close to the maximum response.
Therefore, LUF6000 cannot enhance Emax much further.
The finding that an antagonist of the A3 AR can be con-
verted into an agonist may represent a novel mechanism
of GPCR activation and may be generalized to other
GPCRs.
Methods
Materials
Adenosine deaminase was obtained from Worthington
Biochemical Corp. (Lakewood, NJ). NECA (adenosine-5'
-N-ethyluronamide), CCPA (2-chloro-N6-cyclopentylade-
nosine) and Cl-IB-MECA (2-chloro-N6-(3-iodoben-
zyl)adenosine-5' -N-methyluronamide) were from Sigma
(MO, USA). LUF6000 (N-(3,4-dichloro-phenyl)-2-
cyclohexyl-1H-imidazo [4,5-c]quinolin-4-amine) and
LUF5833 (2-aminophenyl-6-(1H-imidazol-2-ylmethyl-
sulfanyl)-pyridine-3,5-dicarbonitrile) were synthesized at
Leiden/Amsterdam Center for Drug Research (Leiden, The
Netherlands). MRS541 (N6-(3-iodobenzyl)adenosine)
and MRS542 (2-chloro-N6-(3-iodobenzyl)adenosine)
were synthesized at NIDDK, National Institutes of Health
(Bethesda, MD, USA). All compounds were stored at -
20°C as DMSO solutions. DMSO was added to the con-
trols in all experiments. [35S]GTPγS (1068 Ci/mmol) was
from Amersham (Buckinghamshire, UK). All other com-
pounds, reagents, or solutions were obtained from stand-
ard commercial sources and were of analytical grade.
Cell Culture
Chinese hamster ovary (CHO) cells stably expressing A1
or A3 AR were maintained at 37°C with 5% CO2 in a 1:1
mixture of Dulbecco's modified Eagle's medium (DMEM)
and Ham's F12 medium, supplemented with 10% fetal
bovine serum (FBS), 100 units/ml penicillin, 100 μg/mL
streptomycin, and 2 mM glutamine.
[35S]GTPγS binding assay
The preparation of membranes from CHO cells stably
expressing human A1 or A3 AR was as previously described
[18]. [35S]GTPγS binding was measured in 200 μl buffer
containing 50 mM Tris HCl (pH 7.4), 1 mM EDTA, 1 mM
MgCl2, 1 μM GDP, 1 mM dithiothreitol, 100 mM NaCl, 3
Units/ml adenosine deaminase, 0.2 nM [35S]GTPγS,
0.004% 3- [(3-cholamidopropyl) dimethylammo-
nio]propanesulfonate (CHAPS), and 0.5% bovine serum
albumin. Incubations were started by addition of the
membrane suspension (5 μg protein/tube) to the test
tubes, and carried out in duplicate for 30 min at 25°C.
The reaction was stopped by rapid filtration through
Whatman GF/B filters, pre-soaked in 50 mM Tris HCl, 5
mM MgCl2 (pH 7.4) containing 0.02% CHAPS. The filters
were washed twice with 3 ml of the buffer mentioned
before, and retained radioactivity was measured using liq-
uid scintillation counting. Non-specific binding of
[35S]GTPγS was measured in the presence of 10 μM unla-
belled GTPγS.
Simulation of concentration-effect curves using MatLab
A mathematical model for allosteric modulation [19] was
implemented in MatLab (version 7.1), a software package
for technical computing. A graphic user interface was
composed to facilitate parameter input and to yield out-
put in the form of simulated curves.
Data analysis
Functional parameters were calculated using Prism 4.0
software (GraphPAD, San Diego, CA, USA). Data were
expressed as mean ± sem. Student's t-test or ANOVA was
used where appropriate for statistical analysis.
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